|
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Metastatic Lung Cancer Overview 7 Therapeutics Development 8 An Overview of Pipeline Products for Metastatic Lung Cancer 8 Metastatic Lung Cancer Therapeutics under Development by Companies 10 Metastatic Lung Cancer Therapeutics under Investigation by Universities/Institutes 11 Mid Clinical Stage Products 13 Comparative Analysis 13 Early Clinical Stage Products 14 Comparative Analysis 14 Pre-Clinical Stage Products 15 Comparative Analysis 15 Metastatic Lung Cancer Therapeutics – Products under Development by Companies 16 Metastatic Lung Cancer Therapeutics – Products under Investigation by Universities/Institutes 17 Companies Involved in Metastatic Lung Cancer Therapeutics Development 18 GlaxoSmithKline plc 18 ARQULE, INC 19 NewLink Genetics Corporation 20 Metastatic Lung Cancer – Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Combination Products 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 ARQ 197 + Tarceva - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 GM.CD40L Cell Vaccine + Cyclophosphamide + Tretinoin - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Aerosolized GM-CSF - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 PANVAC-F + PANVAC-V + Therapeutic Autologous Dendritic Cells - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Cyclophosphamide + Vaccine Therapy - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 35 Carboplatin + TS-1 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Cisplatin + Thiosulfate - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Decitabine + Romidepsin - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 isolated perfusion + paclitaxel - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 GSK1120212 + Erlotinib - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 GSK1120212 + Pemetrexed - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 GSK1120212 + Nab-Paclitaxel - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 GSK1120212 + Pemetrexed + Carboplatin - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 MVF-HER-2(628-647)-CRL 1005 Vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 GSK1363089 + Erlotinib Hydrochloride - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 romidepsin - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 D-1MT + Taxotere - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 CpG DNA Lipoplex - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Vaccine For Metastatic Lung Cancer - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Metastatic Lung Cancer Therapeutics – Drug Profile Updates 56 Metastatic Lung Cancer Therapeutics – Discontinued Products 57 Metastatic Lung Cancer Therapeutics - Dormant Products 58 Metastatic Lung Cancer – Product Development Milestones 59 Featured News & Press Releases 59 Jun 20, 2011: Momenta Announces Publication Of Preclinical Results Of Oncology Drug M402 In PLoS One 59 Jun 10, 2011: CureVac Presents Promising New Data For Lung Cancer Vaccine CV9201 At ASCO Conference 59 May 19, 2011: VBL Therapeutics Presents Preclinical Data For VB-111 At 14th Annual ASGCT Meeting 60 Nov 10, 2010: Silence Reports Positive Preclinical Research Findings Of Atu027 In Pulmonary Metastasis Animal Models 60 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 63 Disclaimer 63
|